Skip to main content

ASA: Embolization of MMA Cuts Risk for Subsequent Subdural Hematoma, Surgery

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 14, 2024.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, Feb. 14, 2024 -- For patients with symptomatic subacute or chronic subdural hematoma (SDH), embolization of the middle meningeal artery (MMA) as an adjunct to surgery reduces the risk for subsequent SDH and need for surgical drainage, according to a study presented at the annual American Stroke Association International Stroke Conference, held from Feb. 7 to 9 in Phoenix.

Jared Knopman, M.D., from Weill Cornell Medical College in New York City, and colleagues examined the safety and effectiveness of Onyx Liquid Embolic System embolization of the MMA as an adjunct to conventional treatment for patients with symptomatic subacute or chronic SDH in a trial that enrolled 400 individuals across 39 U.S. centers. Individuals who met the criteria for surgical evacuation were randomly assigned to receive surgery alone or surgery with adjunctive MMA embolization in a 1:1 ratio.

The researchers found that subsequent subdural hematoma within 90 days and need for surgical drainage occurred in 4.1 and 11.3 percent of those who underwent surgery plus embolization and surgery alone, respectively. Increasing disability and neurological dysfunction were comparable in both groups at 90 days after surgery, occurring in 11.9 and 9.8 percent of patients, respectively. Overall, 2 percent of patients who received embolization had serious adverse events attributed to embolization.

"The EMBOLISE trial showed that there was a nearly threefold reduction in re-operation for patients that were treated with surgery plus embolization," coauthor Jason Davies, M.D., Ph.D., from the State University of New York at Buffalo, said in a statement. "Fewer trips to the operating room mean less potential for pain, complications, recovery, and expense for the patient."

The study was funded by Medtronic Neurovascular Clinical Affairs. The Onyx Liquid Embolic System is manufactured by EV3, which is owned by Medtronic.

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

Emergency Inguinal Hernia Surgery Rates Increased With Lower Country Income

FRIDAY, May 31, 2024 -- For patients undergoing inguinal hernia surgery, emergency surgery rates increase from high- to low-income countries, according to a study published online...

Delay in Hospital Arrival After Stroke Linked to Social Vulnerability

THURSDAY, May 30, 2024 -- Areas with a high incidence of delay in hospital arrival after ischemic stroke are characterized by increased social vulnerability, according to a study...

Infarct Size Does Not Affect Treatment Effect of Early Versus Late DOAC

TUESDAY, May 28, 2024 -- For individuals with minor, moderate, or major stroke, the treatment effect of early versus late direct oral anticoagulant (DOAC) initiation does not...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.